Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_assertion description "[Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_assertion evidence source_evidence_literature NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_assertion SIO_000772 23561477 NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_assertion wasDerivedFrom befree-20140225 NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_assertion wasGeneratedBy ECO_0000203 NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.
- befree-20140225 importedOn "2014-02-25" NP202302.RAku88GjhYV9KXQUSILu2grvN3OTSI_8iC6C0hhXdRBgc130_provenance.